Department of Microbiology/Biotechnology, Interfaculty Institute of Microbiology and Infection Medicine, Tübingen (IMIT), Cluster of Excellence 'Controlling Microbes to Fight Infections', University of Tübingen, Auf der Morgenstelle 28, 72076 Tübingen, Germany.
Research Center for Biotechnology, Indonesian Institute of Sciences (LIPI), Jl. Raya Jakarta-Bogor KM.46, Cibinong, West Java 16911, Indonesia.
Mar Drugs. 2021 May 28;19(6):316. doi: 10.3390/md19060316.
Indonesia is one of the most biodiverse countries in the world and a promising resource for novel natural compound producers. Actinomycetes produce about two thirds of all clinically used antibiotics. Thus, exploiting Indonesia's microbial diversity for actinomycetes may lead to the discovery of novel antibiotics. A total of 422 actinomycete strains were isolated from three different unique areas in Indonesia and tested for their antimicrobial activity. Nine potent bioactive strains were prioritized for further drug screening approaches. The nine strains were cultivated in different solid and liquid media, and a combination of genome mining analysis and mass spectrometry (MS)-based molecular networking was employed to identify potential novel compounds. By correlating secondary metabolite gene cluster data with MS-based molecular networking results, we identified several gene cluster-encoded biosynthetic products from the nine strains, including naphthyridinomycin, amicetin, echinomycin, tirandamycin, antimycin, and desferrioxamine B. Moreover, 16 putative ion clusters and numerous gene clusters were detected that could not be associated with any known compound, indicating that the strains can produce novel secondary metabolites. Our results demonstrate that sampling of actinomycetes from unique and biodiversity-rich habitats, such as Indonesia, along with a combination of gene cluster networking and molecular networking approaches, accelerates natural product identification.
印度尼西亚是世界上生物多样性最丰富的国家之一,也是新型天然化合物产生菌的有前途的资源。放线菌产生了大约三分之二的临床使用的抗生素。因此,开发印度尼西亚的微生物多样性以寻找放线菌可能会发现新的抗生素。从印度尼西亚的三个不同独特地区共分离出 422 株放线菌菌株,并测试其抗菌活性。九株具有强大生物活性的菌株被优先用于进一步的药物筛选方法。这九株菌株在不同的固体和液体培养基中培养,并结合基因组挖掘分析和基于质谱(MS)的分子网络分析来鉴定潜在的新型化合物。通过将次生代谢物基因簇数据与基于 MS 的分子网络结果相关联,我们从这九株菌株中鉴定出了几种基因簇编码的生物合成产物,包括萘啶霉素、阿米卡星、埃希霉素、替兰霉素、安密霉素和去铁胺 B。此外,还检测到 16 个假定的离子簇和许多基因簇,这些基因簇无法与任何已知的化合物相关联,表明这些菌株可以产生新型的次生代谢物。我们的结果表明,从印度尼西亚等独特且生物多样性丰富的栖息地中采集放线菌,结合基因簇网络和分子网络分析方法,可以加速天然产物的鉴定。